Chris Meduri, MD MPH

Husband to @audrameduri. Father. Traveler.
Interventional Cardiologist at Karolinska &
Chief Medical Officer of @anteristech
#TAVR #TMVR #TreatTR

[MIЯVΛƬ #IC ༄ ｡° @mirvatalasnag]

#NYValves2024 @crfheart

@JoaoLCavalcante presents the First in Human #DurAVR results

❓Why another BEV? Unique Flow displacement characteristics & promising early imaging data

🔹20 point biomimetic improvement in LV mass

LV remodeling & restoration of laminar flow hence Ao stiffness

[Cardiovascular News @CN_publishing]

Insights of FIH and EFS use of DurAVR (@AnterisTech) a single-leaflet design biomimetic valve are presented at #EuroPCR by Chris Meduri

[Chris Meduri, MD MPH @chrismeduri]

@shonmd Fantastic news! Congrats!

[Chris Meduri, MD MPH @chrismeduri]

@AndreasRck2 @pcr Outstanding work Aninda!

[Cardiovascular News @CN_publishing]

#PCRLV: @azeemlatib presents insights from the first in man implant of the DurAVR biomimetic TAVI valve (@AnterisTech). He reports that the device had a favourable safety profile, and “outstanding” haemodynamic performance

[Andrea Scotti @AndreaScotti21]

⭐️ FIH & EFS data on DurAVR just presented by @azeemlatib #PCRLV

🎯Balloon-expandable
🎯Commissure-alignment
🎯Long coaptation length
🎯EXCELLENT Hemodynamics

@chrismeduri @AnterisTech @MonteHeart

[Chris Meduri, MD MPH @chrismeduri]

Visionary work led by @HEARTinMagnet looking at the impact of aortic flow abnormalities on CV disease. Likely an important feature in future AVR development. @JoaoLCavalcante @hahn_rt @J_Sathananthan @sellers_steph

[Nature Reviews Cardiology @NatRevCardiol]

Check out our latest Perspectives article on the link between aortic flow-related abnormalities and cardiovascular disease by Pankaj Garg and colleagues | https://t.co/k0QxCFzoUF

[Wayne Paterson @CEOPaterson]

Great week at TCT with incredible data being presented by Anteris demonstrating superior MPG's ,superior EOA's and superior DVI's to current therapies. A huge thanks to our team,Physicians and patients. We are moving the conversation forward ! #proudtobeanteris #DurAVR

[Pankaj Garg @HEARTinMagnet]

An insight into why aortic flow is becoming a novel therapeutic target.
In collaboration with world experts in aortic physiology. @NatureNews @NatRevCardiol @Nature
#WhyCMR #4DFlowCMR
Thanks ALL (@chrismeduri) and legendary Michael Markl!
Paper ⬇️
https://t.co/9AUHY3CZsw

[Chris Meduri, MD MPH @chrismeduri]

DurAVR US EFS results presented @TCTMD by @azeemlatib today

In small annuli patients (mean 22.2):

✔️ safe, easy to use
✔️ no pacemakers
✔️ 93% no/trace, 7% mild PVL

🎯mean EOA 2.36
🎯MPG 7.8
🎯DVI 0.71

This groundbreaking, first biomimetic valve will change AS treatment

[Chris Meduri, MD MPH @chrismeduri]

@OKhaliqueMD @Rocket2010 @umichCVC @TCTMD @PCRonline @AnterisTech @ShinFukuharaMD @azeemlatib @DrTomWaggoner @tavrkapadia @TAVRBot @CEOPaterson @hahn_rt @JoaoLCavalcante Thanks for all of your teams help!

[Chris Meduri, MD MPH @chrismeduri]

It is with great pleasure to announce the completion of the DurAVR EFS enrollment! Thank you @umichCVC. This first-in-class biomimetic valve exceeded already remarkable prior results. More details next week in San Fran @TCTMD and in London as a LBCT @PCRonline. @AnterisTech #tavr

[Chris Meduri, MD MPH @chrismeduri]

Congratulations to the incredible team @ClevelandClinic for 3 great DurAVR cases last week. All with excellent results! Always great seeing good friends Rishi Puri Amar Krishnaswamy @tavrkapadia and super fellow @Triplet_Trav ! Look forward to more soon! #tavr @PCRonline @TCTMD

[Chris Meduri, MD MPH @chrismeduri]

Congratulations to @DrTomWaggoner and his team on 2 outstanding DurAVR cases this week. Seeing your team do a pristine case in only 20 minutes is a testament to your whole program! Look forward to many more soon. @AnterisTech

[Thomas Waggoner @DrTomWaggoner]

Congrats to our phenomenal TMC SHD & CV Research Teams for implanting the first 2 DurAVR biomimetic TAVRs in ARIZONA, 2nd in the US! This could be transformative technology in the TAVR space. Will be very interesting to see how fast this potential disruptive advancement grows!

[Chris Meduri, MD MPH @chrismeduri]

Incredibly work by @MonteHeart and proud of @AnterisTech to announce the first patients enrolled in the DurAVR US EFS study. The first US patients treated with a biomimetic valve! Incredible results, small annuli with mean EOA of 2.2 and mean gradient of 4 acutely! @azeemlatib

[Chris Meduri, MD MPH @chrismeduri]

An incredible result for this patient from a remarkable team. Congrats Anita Asgar and team! More to come!
@J_Sathananthan @JoaoLCavalcante @hahn_rt @modine_thomas @drnvanmieghem @AndreasRck2 @GilbertTangMD @DrTomWaggoner @GAilawadiMD @sellers_steph @azeemlatib @bapat_savrtavr

[Anteris Technologies @AnterisTech]

#AnterisTech announces the first #ValveInValve procedure with #DurAVR™ THV has been completed by Dr. Anita Asgar in #Canada as part of Health Canada’s Special Access Program. $AVR #TAVR #TAVI #Innovation #ProudtobeAnteris

Read the Full Announcement: https://t.co/xtojctWhqT

[Chris Meduri, MD MPH @chrismeduri]

@BidmcCvi @BIDMChealth @BIDMC_Medicine @rwyeh @BIDMCVFellows A living legend to all those who had the pleasure of training with him.

[Chris Meduri, MD MPH @chrismeduri]

Great article by @michaelTCTMD on the impact/importance of no-implant shunts. RF allows for a durable septectomy.

[TCTMD @TCTMD]

No-Implant Shunt for HF Looks Safe, Feasible in Early Snapshot https://t.co/DSL7yhsMwQ

[Anteris Technologies @AnterisTech]

.@chrismeduri presents the latest data from the DurAVR™ THV FIH Study demonstrating sustained haemodynamic performance at 1 year. #TAVR $AVR #TAVI #cardiology #AnterisTech #TVT2023

[Anteris Technologies @AnterisTech]

#Anteristech announces powerful new data from the DurAVR™ THV FIH Study demonstrating sustained haemodynamic performance at 1 year in 12 patients. #TAVR $AVR #TAVI #cardiology #AnterisTech

Read Full Announcement: https://t.co/GdPXHMlr5r